Innoviva (INVA)
(Delayed Data from NSDQ)
$19.69 USD
+0.17 (0.87%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $19.67 -0.02 (-0.10%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.69 USD
+0.17 (0.87%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $19.67 -0.02 (-0.10%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum C VGM
Zacks News
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.
Top Ranked Value Stocks to Buy for April 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, April 23rd.
Should Value Investors Buy Innoviva (INVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Innoviva's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Innoviva.
Top Ranked Value Stocks to Buy for April 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, April 16th
Top Ranked Momentum Stocks to Buy for April 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 16th
Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day
Another Drug to Fight Coronavirus & 3 Picks
by Sejuti Banerjea
Another drug is being tested to kill the virus (if we can figure out administration on humans).
Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA
by Zacks Equity Research
Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
Sanofi (SNY) Catches Eye: Stock Jumps 5.3%
by Zacks Equity Research
Sanofi (SNY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
New Strong Buy Stocks for March 6th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
5 Stocks to Grab as Gold Prices Surge on Coronavirus Fears
by Madhurima Das
Gold prices are currently at seven-year highs as investors are flocking to buy gold amid fears of the coronavirus outbreak and economic slowdown.
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.
Innoviva (INVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Innoviva (INVA) closed at $13.91 in the latest trading session, marking a +0.87% move from the prior day.
Jazz Enrolls First Patient in Phase II/III Leukemia Study
by Zacks Equity Research
Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases
Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease
by Zacks Equity Research
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.
BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China
by Zacks Equity Research
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.
Alnylam Stock Up More Than 61% YTD on Pipeline Progress
by Zacks Equity Research
Shares of Alnylam (ALNY) rise on significant pipeline progress.
Top Ranked Value Stocks to Buy for December 30th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 30th.
Innoviva (INVA) Stock Moves -0.84%: What You Should Know
by Zacks Equity Research
Innoviva (INVA) closed at $14.25 in the latest trading session, marking a -0.84% move from the prior day.
Top Ranked Value Stocks to Buy for December 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 26th.
AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod
by Zacks Equity Research
AstraZeneca (AZN) gets approval in China for PT010, its triple-combo inhaler, a fixed-dose ICS/LABA/LAMA inhaler, to treat COPD.
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
by Zacks Equity Research
Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.
Top Ranked Value Stocks to Buy for December 20th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 20th.
Epizyme Stock Up on Positive Advisory Votes for Tazemetostat
by Zacks Equity Research
Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.